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Abstract
To resist to b-lactam antibiotics Eubacteria either constitutively synthesize a b-lactamase or a low affinity penicillin-binding
protein target, or induce its synthesis in response to the presence of antibiotic outside the cell. In Bacillus licheniformis and
Staphylococcus aureus, a membrane-bound penicillin receptor (BlaR/MecR) detects the presence of b-lactam and launches a
cytoplasmic signal leading to the inactivation of BlaI/MecI repressor, and the synthesis of a b-lactamase or a low affinity
target. We identified a dipeptide, resulting from the peptidoglycan turnover and present in bacterial cytoplasm, which is
able to directly bind to the BlaI/MecI repressor and to destabilize the BlaI/MecI-DNA complex. We propose a general model,
in which the acylation of BlaR/MecR receptor and the cellular stress induced by the antibiotic, are both necessary to
generate a cell wall-derived coactivator responsible for the expression of an inducible b-lactam-resistance factor. The new
model proposed confirms and emphasizes the role of peptidoglycan degradation fragments in bacterial cell regulation.
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Introduction
The introduction of penicillin, a b-lactam antibiotic, to treat
bacterial infection, has drastically reduced the cases of human
morbidity and mortality. However, a tight control of these
bacterial pathogens has never been achieved and the use of b-
lactam antibiotics appears to be linked to the selection and the
spread of b-lactam resistant clinical isolates. In these strains, b-
lactam antibiotic resistance can be obtained by one of the three
following mechanisms: (i) inactivation of the b-lactam molecule by
a specific hydrolase, the b-lactamase [1–3]; (ii) alteration of the b-
lactam targets, the membrane-bound D,D-transpeptidases, that
renders them insensitive to the action of the antibiotic [4]. These
enzymes, which catalyze the final step of the bacterial cell wall
biosynthesis, are inactivated by penicillin through acylation of
their active serine by the antibiotic. For this reason, these enzymes
are reported in the literature as Penicillin-Binding Proteins (PBPs)
[3,5] and (iii) prevention of b-lactams from reaching their targets.
This mechanism of resistance is only found in Gram-negative
bacteria and can be due to the alteration of porins and/or the
presence of an efflux pump [6–8].
In Gram-negative bacteria, the presence of a b-lactamase,
sometimes in synergy with decreased outer membrane permeabil-
ity or efflux systems, is the main resistance factor [9] whereas a
low-affinity PBP (resistant PBP) is the most frequent factor
encountered in Gram-positive bacteria [3].
In Eubacteria, b-lactamases can be either constitutively
expressed or induced by a sub-lethal concentration of b-lactam
antibiotic outside the cell [10]. The Staphylococcus aureus BlaZ and
Bacillus licheniformis 749/I BlaP b-lactamases are under the control
of at least three different gene products: BlaI, BlaR1 and BlaR2
homologous for both species. BlaI and BlaR1 act as a cytoplasmic
repressor and a membrane-bound penicillin receptor, respectively
[11]. The implication of a blaR2 gene has been deduced from
genetic studies but this is not yet demonstrated [12,13]. On the
bacterial chromosome, blaP/Z, blaR1 and blaI are clustered in a
divergon (bla divergon) in which blaR1 and blaI form an operon
(Figure 1A). Similarly, two regulatory genes, mecR1 and mecI,
homologous to blaR1 and blaI, have been identified in S. aureus and
are involved in the induction of the low affinity PBP2a (encoded by
mecA gene). The two regulatory genes are organized in an operon
and form, together with mecA, a divergon (mec divergon). In the
induction of PBP2a, the MecI and MecR1 proteins have the same
function as BlaI and BlaR1 [14]. In addition, sequence similarities
between the promoter-operator regions of the mecA and blaZ/P
divergons have been observed. Furthermore, the purified MecI
and BlaI bind mec/bla operators [15,16]. In vivo, the mecR1 operon
regulates the PBP2a production in S. aureus [17] and if the
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002571staphylococcal MecI and BlaI repressors are interchangeable, the
BlaR1/MecR1 penicillin receptors are not. Indeed, the comple-
mentation of a mecR1 mutation present in the mec divergon cannot
be achieved by the S. aureus blaR1 [17].
In the absence of b-lactam antibiotic (further referred as the
inducer), the BlaP/BlaZ b-lactamase synthesis and blaIR1 operon
expression remain low thanks to the binding of the homodimeric
BlaI repressor to its operator in the bla divergon (Figure 1A).
BlaR1 acylation by the antibiotic launches a cytoplasmic, receptor-
dependent signal that will lead to BlaI inactivation. Consequently,
the derepression of the blaZ/blaP and blaIR1 genes increases the b-
lactamase synthesis by the bacterial cell. In 2001, Zhang et al have
proposed a mechanism explaining the b-lactamase induction in S.
aureus [18]. In this model, the first consequence of the acylation of
the BlaR1 sensor domain is the single point cleavage of its L3
cytoplasmic loop. This cleavage converts the putative inactive L3
metalloprotease domain into an active form (Figure 1B). Next, the
activated L3 metalloprotease directly or indirectly inactivates BlaI
by cleavage of the peptide bond linking the N101 and F102
residues (Figure 1C). The cleaved BlaI repressor exhibits a low
affinity for its nucleic operator and no longer represses the
transcription of bla divergon. In this model, BlaR2 could be
activated by BlaR1 to cleave BlaI or involved in BlaR1 activation
(Figure 1C). In the latter case, the activated BlaR1 would be
directly responsible for the BlaI cleavage. Although this model can
describe the fate of BlaI/MecI in S. aureus, the molecular details
underlying the induction mechanism remain unclear. This aspect
has been highlighted when the three dimensional structures of the
staphylococcal BlaI and MecI proteins were obtained. Indeed,
these structures showed that the site of cleavage was buried and
inaccessible to the solvent [14,19]. In B. licheniformis 749/I, the fate
of BlaI during the BlaP induction is similar to that described for
the staphylococcal repressor, except that in that organism, BlaI is
completely degraded during the induction [12]. However,
unexpectedly, in a Bacillus subtilis 168 strain carrying a plasmid
harbouring the B. licheniformis blaP-blaI-blaR1 divergon
(pDML995), the BlaP b-lactamase is induced in the B. subtilis
genetic background and the BlaI repressor is inactivated without
proteolysis [12,20]. The ability of this recombinant B. subtilis 168/
pDML995 (BS995) to induce the BlaP b-lactamase implies that an
orthologous blaR2 gene is present in the B. subtilis 168 genome and
that the inactivation of BlaI could be the result of the presence of a
coactivator produced independently of the presence of the bla
divergon [12]. Furthermore, from kinetic studies of the BlaP
induction, Duval et al [21] deduced that two conditions must be
fulfilled to achieve b-lactamase induction in B. licheniformis 749/I:
(i) BlaR1 must be activated by the b-lactam antibiotic and (ii) the
antibiotic must generate an intracellular penicillin stress. All these
results (obtained in Bacillus) and the buried cleavage site in the
three-dimensional structures of the staphylococcal BlaI/MecI
repressors suggest the presence of a molecule inactivating BlaI/
MecI (Figure 1D). To probe this hypothesis, we have revisited the
induction mechanism by searching for the presence of a
coactivator.
Results
A cytoplasmic coactivator that inactivates BlaI is present
in the cytoplasm of induced B. subtilis/pDML995 (BS995)
In a previous work, File ´e et al have postulated the presence of a
coactivator in the cytoplasm of induced BS995 cells [12]. To check
this hypothesis, we have prepared small-scale soluble crude cellular
extracts of non-induced and induced BS995 cells (for details see
Materials and Methods). These extracts were ultrafiltrated on a
10 kDa cut-off membrane to eliminate high-molecular-mass
macromolecules, and submitted to a fluorescent electrophoretic
mobility shift assay (EMSA) [22]. As shown in figure 2A, only the
partially purified induced cellular fraction is capable to destabilize
the interaction between the dimeric B. licheniformis BlaI repressor
and its nucleic operator (BlaI)2.OP. When the ultrafiltrated
fraction of the induced cellular extract was incubated for 10 min
at 100uC and resubmitted to EMSA, no heat effect was detected.
The remaining heated fraction was further fractionated by
ultrafiltration on a 5 kDa cut-off membrane and the resulting
ultrafiltrated material retained its ability to disrupt the (BlaI)2.OP
complex (data not shown). At this step, we concluded that a
thermostable coactivator with a molecular mass lower than or
equal to 5 kDa was present in the cytoplasm of induced BS995
cells, which was responsible for the inactivation of BlaI during the
induction process.
To determine when the production of coactivator reaches its
maximum during the induction process, small-scale soluble
cellular extracts of induced BS995 cells were prepared every
15 min from 0 to 180 min after the addition of the inducer. By
fluorescent EMSA, the production of coactivator reached a
maximum level between 75 and 105 min after the addition of
the inducer (Figure S1 in Text S1). This result is in agreement with
the maximum rate of b-lactamase synthesis that is reached after
80–90 min in B. licheniformis 749/I or BS995 [21]. In the following
experiments, it was assumed that the peak of coactivator
production was reached 90 min after the addition of the inducer.
To characterize the coactivator, a large scale extract was
prepared by inducing BS995 cells and harvesting 90 min after the
addition of the inducer. This cellular extract was heat-treated,
partially purified by ultrafiltration on a 10 kDa cut-off membrane
and freeze-dried. The dried residue was then dissolved in 50 mM
NH4HCO3 (pH 7.8) buffer and submitted to molecular sieving on
a Sephadex G-25 column (16100 cm) equilibrated in the same
buffer. The chromatogram obtained by monitoring the eluate
absorbance at 215 nm supplied eight major peaks (F1,… ,F 8,
Figure S2 in Text S1) and the corresponding fractions were pooled
and freeze-dried. Only the F5 peak showed an ability to destabilize
Author Summary
Beta-lactamases are enzymes produced by some bacteria
and are responsible for their resistance to beta-lactam
antibiotics like penicillin. Among these bacteria some of
them possess a beta-lactamase that is only produced at a
high level when a beta-lactam antibiotic is present outside
the cell. This mechanism of regulation, named beta-
lactamase induction, has been described both in Gram-
negative and Gram-positive bacteria. In Staphylococcus
aureus and Bacillus licheniformis, two Gram-positive
bacteria, their beta-lactamase is induced by homologous
proteins including a membrane-bound penicillin receptor,
BlaR1, and a cytoplasmic DNA-binding protein, BlaI, acting
as repressor. The first step in the induction mechanism is
the acylation of the extracytoplasmic domain of BlaR
receptor by the beta-lactam antibiotic concomitant with
the activation of the peptidase activity of its cytoplasmic
domain. The activated receptor launched a cytoplasmic
signal leading to the inactivation of BlaI repressor. The
nature of this cytoplasmic signal is not well understood. In
our study, we identified that a dipeptide issued from the
bacterial cell wall is able to inactivate the BlaI repressor. It
is the first time that a cell wall fragment is shown to
reenter in the cytoplasm of Gram-positive bacteria to
regulate gene expression.
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PLoS Pathogens | www.plospathogens.org 2 March 2012 | Volume 8 | Issue 3 | e1002571Figure 1. Beta-lactamase induction in B. licheniformis 749/I and S. aureus. (A) Organization of bla divergon: on the B. licheniformis 749/I
chromosome, blaP, blaI and blaR1 form a divergon; the transcription of blaI results in the biosynthesis of a dimeric BlaI repressor that binds to three
operators (OP1, OP2 and OP3) located between the blaP and blaIR1 operons, preventing blaP, blaI and blaR1 transcriptions. A similar gene
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(Figures 2B and S2 in Text S1). The estimated average molecular
mass of the components in the F5 peak varied from 300 to 600 Da,
an estimation obtained by comparing the average distribution
constant (Kav=0.62) of F5 fractions to those obtained for tryptic
peptides [23] or for a small molecule such as 6-amino-penicillanic
acid (216 Da, Kav=0.66) [24]. At this point, we postulated that
the coactivator generated by the penicillin-induction was a
molecule with a molecular mass in the 300–600 Da range. Thus,
the next question concerned the origin of this coactivator.
In their study of the BlaP induction of B. licheniformis, Duval et al
[21] stated that two conditions must be fulfilled to allow induction,
namely (i) the acylation of the BlaR receptor by the b-lactam
antibiotic and (ii) a cellular stress probably due to the partial
acylation of PBP1 by the b-lactam. The latter condition suggests
that the PBP1 acylation could trigger a higher autolytic activity
leading to an overproduction of peptidoglycan fragments outside
the cell. These fragments could be transported into the bacterial
cell by an unknown mechanism and one of them, modified by the
activated BlaR1, could act as the coactivator. To investigate this
hypothesis, various peptidoglycan fragments were assayed for their
ability to destabilize the (BlaI)2.OP complex.
The coactivator is a peptidoglycan fragment
The various peptidoglycan fragments or related molecules listed
in Table 1 were tested by fluorescent EMSA. Among these 20
compounds, only two peptides, c-D-Glu-m-A2pm (dipeptide 1,
where A2pm represents diaminopimelic acid) and c-D-Glu-L-Lys
(dipeptide 2), derived from Bacillus subtilis and S. aureus peptido-
glycans, respectively, can dissociate the B. licheniformis (BlaI)2.OP
complex. Both compounds tested on the homologous staphylo-
coccal MecI repressor showed the same effect. To confirm the
positive results obtained with the highly sensitive fluorescent
EMSA, the experiments were repeated by using the less sensitive
EMSA performed with an agarose gel as separation matrix. Under
these conditions, higher concentrations of BlaI and operator could
be used and more reproducible results were obtained. Dissociation
of the (BlaI)2.OP complex was again observed and a titration of the
repressor/DNA complexes by their respective dipeptides per-
formed (Figure 3). From these data, the concentration of dipeptide
allowing the displacement of 50% of bound BlaI/MecI to their
nucleic operators was estimated at about 2 mM.
At this step, it could be concluded that the molecule responsible
for the inactivation of BlaI/MecI was a dipeptide derived from
peptidoglycan.
Identification of the coactivator present in the BS995
cellular extract
In order to establish whether dipeptide 1 was present in the
active F5 fraction, we examined the sample elution pattern by RP-
HPLC. When analyzed by HPLC on a C18 reverse-phase column
in acidic condition (0.1% trifluoroacetic acid (TFA) in water
(buffer A), dipeptide 1 was not retained by the hydrophobic matrix
and eluted in the void volume of the column. To overcome this
problem, dipeptide 1 was modified with 2,4,6-trinitrobenzene
sulfonic acid (TNBS). Upon reaction with TNBS, primary amines
form a highly chromogenic trinitrophenyl-derivative (TNP-),
which is more hydrophobic and can be detected at 335 nm. As
dipeptide 1 contains two free amino groups, two peaks
corresponding to the mono- and di-TNP derivatives of this
compound were observed, which were eluted at 35% and 55% of
acetonitrile, respectively.
Next, in the text, only the results obtained for the fraction eluted
at 35% of acetonitrile will be reported; the same conclusions are
valid for the second fraction. Analysis of the TNBS-modified
fraction by RP-HPLC showed that a peak corresponding to
dipeptide 1 was present in the F5 fraction. This peak was
specifically enriched by affinity chromatography when BlaI2.OP
was used to trap the dipeptide 1 present in this fraction (see Figure
S3 in Text S1). Furthermore, the enriched peak co-eluted with
synthetic dipeptide 1 when the latter was added to the F5 fraction
before TNBS modification. At this step, it was concluded that
dipeptide 1 was effectively present in induced BS995 cells.
The coactivator directly interacts with the C-terminal
domain of BlaI/MecI
To point out a direct molecular interaction between the BlaI/
MecI proteins and dipeptides 1 and 2, NMR saturation transfer
difference (STD) experiments were carried out. STD is particu-
larly well adapted to detect ligands that weakly bind to their
protein receptors (dissociation constants, Kd, in the mM range,
[25]).
First, for STD experiments, a narrow frequency region of BlaI/
MecI proton resonances where proton dipeptide resonances are
absent was selectively saturated. Due to the large molecular mass
of BlaI/MecI, spin diffusion is able to progressively propagate the
saturation to other repressor protons, including the area of the
putative binding pocket. In the case of complex formation between
BlaI/MecI and one of the two dipeptides, the saturation will be
also transferred to the bound dipeptide which in turn is rapidly
exchanged from its bound form to its free form in solution. Since
ligands are typically small molecules with long relaxation times,
the saturation information is able to persist for a long time during
which new previously unsaturated ligands can also bind with
saturated BlaI/MecI. In this way, the population of saturated
ligands in solution increases and the corresponding proton ligand
resonances can be detected.
Thus, to highlight the interaction of the BlaI repressor with the
c-D-Glu-m-A2pm dipeptide and the association of the MecI
protein with the c-D-Glu-L-Lys dipeptide, STD experiments were
performed on both systems (Figures 4 and S4 in Text S1). First, the
STD experiment was performed on samples containing only the
ligand or only the protein. Then, the spectra were recorded on
mixtures including one of the proteins and its cognate dipeptide
(Figure 4A–B). For BlaI and MecI, the presence of peptidoglycan
fragment resonances in the STD experiment clearly demonstrated
a saturation transfer from the protein to the dipeptide. This
revealed a direct interaction between the B. licheniformis BlaI and
organization is present in S. aureus. (B) Activation of BlaR/MecR membrane-bound penicillin receptor by a b-lactam: BlaR/MecR is a membrane protein
constituted by two domains: a N-terminal domain (BlaR-NTD) containing four transmembrane segments and an extracellular C-terminal domain
(BlaR-CTD) able to bind penicillin; when a b-lactam is present outside the cell, BlaR-CTD is acylated and a signal is transmitted through
transmembrane segments to the BlaR-NTD intracellular domain that leads to the proteolytic activation of its metalloprotease activity. (C and D) BlaI
inactivation:I nS. aureus, BlaI would be directly or indirectly cleaved by the activated metalloprotease, the resulting degraded repressor loses its
ability to bind DNA and the expression of the resistance gene is launched. In BS995, BlaI inactivation could be the result of the presence of a
coactivator.
doi:10.1371/journal.ppat.1002571.g001
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PLoS Pathogens | www.plospathogens.org 5 March 2012 | Volume 8 | Issue 3 | e1002571the c-D-Glu-m-A2pm dipeptide. Similarly, we observed an
association between the S. aureus MecI and the c-D-Glu-L-Lys
fragment.
In addition, to investigate the effect of the binding of dipeptides
1 and 2 to the proteins, the complex formation was followed by
recording
15N-
1H heteronuclear correlation spectra of samples
containing
15N BlaI or
15N MecI proteins in the absence or
presence of dipeptide (Figure 4A). For both proteins, chemical
shifts or line intensity variations were induced by the addition of an
excess of dipeptide (BlaI/dipeptide: 1/50), confirming a specific
interaction with the peptidoglycan fragments.
However, in both cases, the chemical shift perturbations
concerned a limited set of protein resonances. Superimposition
of the spectra previously obtained with the BlaI/MecI N-terminal
domains [26] onto those obtained for full-length BlaI/MecI in
presence of their coactivator highlighted that the N-terminal
domains did not interact with the dipeptides. These results
suggested that the coactivator-binding site was located in the
repressor C-terminal domains. However, due to the small
dispersion of the C-terminal resonances [26], a more specific
localization of the interaction surface was not feasible.
Thermodynamic characterization of the MecI/c-D-Glu-L-
Lys association
Isotopically enriched S. aureus
15N-MecI was titrated with
unlabeled c-D-Glu-L-Lys coactivator. After each addition of
dipeptide, a two dimensional
1H-
15N correlation spectrum of
15N-labeled protein was recorded and MecINdipeptide concentra-
tions were determined by following chemical shift variations
detected on the C-terminal resonances of the repressor. The
dissociation constant of MecINdipeptide complex was determined
by using the following scheme in which one dipeptide molecule is
bound by the MecI monomer independently of the presence of
MecI dimer.
MecIzdipeptide'
Kd
MecI.dipeptide
The fitting of the data obtained were in agreement with this
scheme and the binding of dipeptide 2 with MecI was
characterized by a Kd value of 862 mM (for more details see
Materials and Methods). Following the same model, the Kd value
obtained by EMSA titration was around 2 mM (Figure 3). In spite
of the great stability of the MecI preparation during NMR
experiments (stable for months at 4uC), the same preparation of
MecI complexed by its dipeptide coactivator was more susceptible
to proteolysis (Figure S5 in Text S1). This observation strength-
ened the explanation of MecI degradation by cytoplasmic
proteases, when inactivated by the coactivator during induction.
Evidence that cytoplasmic enzymes involved in
peptidoglycan catabolism are linked to BlaP induction
The identification of the c-D-Glu-m-A2pm as a cytoplasmic B.
licheniformis BlaI inactivator suggests the presence of a protein
machinery capable to generate this dipeptide from peptidoglycan
catabolism. On the basis of this hypothesis, we have analyzed the B.
subtilis protein database to find enzymes that could be involved in
the hydrolysis of cytoplasmic peptidoglycan fragments. To do so, we
searched the B. subtilis proteome for an ortholog of the Escherichia coli
cytoplasmic L,D-carboxypeptidase (LdcA) which is involved in
peptidoglycan recycling by releasing the terminal D-Ala from L-
Ala-c-D-Glu-m-A2pm-D-Ala [27]. In B. subtilis proteome, we
identified the YkfA protein, a putative cytoplasmic L,D-carboxy-
peptidase (30% of sequence identity with E. coli LdcA). On the B.
subtilis chromosome, the ykfA gene is included in an operon
containing three other genes ykfB, C and D (ykfABCD operon). The
functions of YkfB and YkfC are known. They are both cytoplasmic
enzymes, with L-Ala-D/L-Glu racemase and c-glutamyl-diaminoa-
cid endopeptidase activities, respectively [28,29]. The ykfD gene
codes for a cytoplasmic protein homologous to the intracellular
component of an oligopeptide ABC transporter [30]. The ykfABCD
operon is also present in the genomes of other Bacillus species
including that of B. licheniformis.
Accordingly, B. subtilis mutant strains carrying chromosomal
deletions of each gene of the ykf operon were assayed for BlaP
induction (for details see Text S1). The results obtained show that
the inactivation of ykfA and ykfB negatively affected the BlaP
induction by reducing the level of b-lactamase production by a
factor of 2 and 1.5, respectively (Figure S7 in Text S1). The
inactivation of ykfC does not have any effect on the induction
mechanism whereas that of ykfD exhibits a delay of one hour in b-
lactamase induction launching (Figures S7, C and D in Text S1).
The lower b-lactamase production in the ykfA
2 and ykfB
2 mutants
confirms that enzymes involved in peptidoglycan catabolism affect
BlaP induction. However, the phenotype obtained for ykfA
2 and
ykfB
2 mutants differs from that described for the BlaR2
2 mutant,
for which a non-inducible b-lactamase phenotype is reported. We
sequenced and compared the complete ykfABCD operon from B.
licheniformis WT and from BlaR2
2 mutant and they are identical in
both strains (data not shown). This result excludes the implication
of the ykfABCD operon in the BlaR2
2 mutant phenotype.
Discussion
Within the limits of the compounds listed in Table 1, the
molecule able to inactivate BlaI/MecI repressors is a dipeptide
consisting of a D-glutamic acid residue linked to a diamino acid
(L-Lys or m-A2pm) via a gamma-glutamyl peptide bond. This
dipeptide is a specific fragment derived from the cross-linking
peptide present in the peptidoglycan of most Gram-negative and
Gram-positive bacteria. In B. subtilis and B. licheniformis, the
MurNAc residue is substituted by the L-Ala-c-D-Glu-m-A2pm-D-
Ala tetrapeptide and cross-linking of the glycan chains occurs
between the carboxyl group of the D-Ala of one chain and the free
amino group of m-A2pm on a flanking chain [31]. In S. aureus L-
Lys replaces m-A2pm in the peptide chain, and the cross-linking
between two adjacent tetrapeptides is achieved via an additional
penta-glycine bridge (L-Ala-c-D-Glu-L-Lys[-e-(Gly)5]-D-Ala [32].
Origin of the dipeptide
An important question that remains to be answered is how the
dipeptide is generated in the cytoplasm. It is well established that,
in all Eubacteria, the peptidoglycan is continuously synthesized
Figure 2. Fluorescent EMSA demonstrate the presence of a coactivator in induced BS995 cellular extracts. (A) Ability of ultrafiltrated
non-induced and induced cellular extracts (molecular mass: #10 kDa) to destabilize the BlaI2.operator complex (BlaI2.OP). After peak integration, the
ratio of bound OP/total OP is 0.32 and 0.57 for induced and non-induced cellular extracts, respectively. EMSA were carried out by using an ALF DNA
sequencer. (B) Ability of the F5 fraction (molecular mass: 300–600 Da) to destabilize the BlaI2.OP complex. This fraction was obtained by fractionating
an induced cellular extract on Sephadex G-25 (for details see Materials and Methods and Supplemental data). In presence of a compound present in
F5 fraction the BlaI2.OP complex is dissociated (lower EMSA). Electropherograms showing free OP and BlaI2.OP complex are provided for control.
doi:10.1371/journal.ppat.1002571.g002
BlaI/MecI Inactivation
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designated as the cell wall turnover and the degrading enzymes
involved in this turnover are the autolytic enzymes. In Enterobac-
teriaceae, the peptidoglycan fragments generated by this catabolic
activity are transported into the cytoplasm and the L-Ala-c-D-Glu-
m-A2pm tripeptide released during this process is efficiently
recycled, i.e. reused for de novo peptidoglycan synthesis [33,34].
In contrast, in Gram-positive bacteria, it has not been shown that
the cell wall fragments generated by the autolytic enzymes are re-
injected into the peptidoglycan biosynthesis pathway. But the
alleged lack of peptidoglycan recycling in the latter group does not
exclude that these fragments could be degraded and reused to
produce other molecules than peptidoglycan precursors. Figure S6
in Text S1 summarizes the cell wall hydrolases that are known to
cleave the B. subtilis/B. licheniformis peptidoglycan. Among these
enzymatic activities, only the peptidase that cleaves the peptide
bond between L-Ala and D-Glu has not been described for any
eubacteria to date. In this way, the final product of all these
catabolic activities is the dipeptide L-Ala-D-Glu. However, L-Ala-
D-Glu can be epimerized to L-Ala-L-Glu by YkfB cytoplasmic
epimerase (an activity also found in all Enterobacteriaceae) and the
hydrolysis of the latter dipeptide could occur by known
dipeptidases. In B. subtilis, the presence of YkfB and YkfC
cytoplasmic enzymes, able to cleave peptides issued from
peptidoglycan, suggests that these substrates generated by
peptidoglycan hydrolases can be present in the B. subtilis
cytoplasm.
During the BlaZ/BlaP/MecA induction process, the easy way
to explain the formation of the dipeptide coactivator is to
hypothesize that the activated BlaR would generate the dipeptide
from L-Ala-c-D-Glu-m-A2pm tripeptide. In this case, BlaR would
act as an L-Ala-aminopeptidase. This is plausible because a His-
Glu-X-X-His motif characteristic of neutral zinc peptidases is
detected within the BlaR/MecR L3 loops. Moreover, in the
neutral zinc peptidases super-family, the M1 subclass is composed
of eukaryotic and prokaryotic proteins that exhibit an aminopep-
tidase activity [35,36]. Besides, specific BlaR mutants in this
neutral zinc-binding motif are unable to induce the synthesis of
BlaP (B. Joris, unpublished results), reinforcing the hypothesis that
BlaR could generate the dipeptide that inactivates the repressor. In
the same way, we propose that the Bacillus pro-coactivator
postulated by File ´e et al [12] is the L-Ala-c-D-Glu-m-A2pm
tripeptide. The same authors have also suggested that the product
of the unknown B. licheniformis blaR2 gene should be involved in the
production of the pro-coactivator. As we have demonstrated that
the c-D-Glu-m-A2pm dipeptide acts as a BlaI coactivator, the
blaR2 gene product could be part of the B. licheniformis cell wall
hydrolases (autolytic system). This is in agreement with the results
obtained by Duval et al [21], who showed that a penicillin stress, in
addition to the BlaR acylation by the b-lactam, is necessary for the
b-lactamase induction in B. licheniformis. This penicillin stress
would stimulate the autolytic system, increasing the cell wall
breakdown, thus explaining the high level of pro-coactivator
generated in the presence of the inducer.
Table 1. Peptidoglycan-related molecules tested for their ability to disrupt BlaI/MecI repressor-operator complexes by EMSA (a).
COMPOUND STRUCTURE BlaI inactivation MecI inactivation Origin
UDP-MurNAc-L-Ala-c-D-Glu-m-A2pm-D-Ala-D-Ala
(b) no no [58]
MurNAc-L-Ala-c-D-Glu-m-A2pm -D-Ala-D-Ala
(b) no no [59]
GlcNAc-MurNAc(anhydro)-L-Ala-c-D-Glu-m-A2pm-D-Ala
(b) no no [60]
GlcNAc-MurNAc(anhydro)-L-Ala-c-D-Glu-m-A2pm
(b) no no [60]
GlcNAc-MurNAc(anhydro) no no [60]
L-Ala-c-D-Glu-L-Lys-D-Ala
(c) no no This work
L-Ala- c-D-Glu-m-A2pm
(b) no no This work
c-D-Glu-L-Lys-D-Ala-D-Ala
(c) no no This work
c-D-Glu-L-Lys-D-Ala
(c) no no This work
c-D-Glu-L-Lys
(c) yes yes This work
c-D-Glu-m-A2pm
(b) yes yes [59] and this work
D-Ala-D-Ala no no This work
c-D-Glu-Gly no no Bachem
L-Glu no no Bachem
L-Gln no no Bachem
A2pm (racemic mixture of LL, DD and meso derivatives) no no Sigma
L-Lys no no Sigma
c-L-Glu-L-Lys no no This work
D-Gln-NH2 no no Bachem
D-Gln no no Bachem
Ac2-L-Lys-D-Ala-D-Ala no no [61]
(a)See Materials and Methods for more details.
(b)Peptidoglycan precursors or fragments derived from E. coli, B. subtilis or B. licheniformis cell walls.
(c)Peptidoglycan fragments derived from S. aureus cell wall.
MurNAc: N-acetyl-muramic acid; GlcNAc: N-acetyl-glucosamine.
doi:10.1371/journal.ppat.1002571.t001
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PLoS Pathogens | www.plospathogens.org 8 March 2012 | Volume 8 | Issue 3 | e1002571The best enzyme candidate to generate the pro-coactivator
from L-Ala-c-D-Glu-m-A2pm-D-Ala tetrapeptide is YkfA that
could act as a L,D-carboxypeptidase. The ykfA inactivation does
not abolish the induction phenomenon but leads to a decrease of
b-lactamase induction. The impairment of b-lactamase induction
in ykfA
2 mutant can be explained by the decrease of intracellular
pro-coactivator concentration resulting in a lower concentration of
coactivator available for BlaI inactivation. The unexpected
negative effect of ykfB inactivation, for which the L-Ala-D-Glu
dipeptide concentration should increase in the cytoplasm, can be
explained by the fact that this dipeptide would act as a competitive
inhibitor of the BlaR aminopeptidase activity. The expected
phenotype for ykfC
2 mutant should be either a more or an
unaffected inducible phenotype. Indeed, this last effect is observed.
This phenotype could be explained by the inactivation of c-
glutamyl-diaminoacid endopeptidase activity and the subsequent
accumulation of the BlaR substrate in the cytoplasm. The delay in
b-lactamase induction for ykfD
2 mutant is in agreement with the
inactivation of a protein involved in a specific metabolite
transport. Notably, if YkfD is a part of an ABC transporter
specific for peptidoglycan fragments generated outside the cell, its
inactivation would generate the depletion of these fragments in the
cytoplasm. The observation of a delay in b-lactamase induction
suggests an alternative transport mechanism for these fragments
taken up by a less efficient ABC transporter. This fact would
explain why the pro-coactivator accumulation needed to launch
BlaP induction takes more time to be reached.
The ykfABCD operon is not found in the S. aureus genomes. This
could be explained by the fact that in the S. aureus peptidoglycan
the cross-linking peptide is different. Nevertheless, S. aureus
possesses all the enzyme activities necessary to cleave its
peptidoglycan, including the glycyl-glycine endopeptidase LytM
enzyme [37,38].
Mechanism of induction
The new model we propose, which is summarized in Figure 5,
combines the integration of two signals generated by the action of
the b-lactam inducer: BlaR1 activation and a cellular penicillin
stress. The triggering event for the generation of these two signals
is the acylation of BlaR1 and of one or several PBP(s) by the
inducer. The acylation of PBPs results in their inactivation and
leads to the perturbation of the cell wall biosynthesis, thereby
provoking the anarchic activity of the autolytic enzymes that
ultimately results in the accumulation of the cell wall fragments in
the cytoplasm. The acylation of the BlaR1 C-terminal sensor
domain by the inducer results in the rearrangement of its
transmembrane segments and the activation of L3 cytoplasmic
loop by self-proteolysis or proteolysis by a cytoplasmic protease.
The activated L3 loop would act as an aminopeptidase to generate
the c-D-Glu-m-A2pm or c-D-Glu-L-Lys coactivators from the
corresponding tripeptides. The binding of the coactivator to BlaI/
MecI would induce a conformational change that would make
them unable to bind their DNA operators and to trigger the
expression of BlaZ/BlaP/MecA. In the cytoplasm, the inactivated
repressor would be hydrolyzed in the case of S. aureus and B.
licheniformis by cytoplasmic proteases whose action would be
facilitated by the binding of the coactivator, as observed during
our NMR experiments with MecI.
In the new model proposed for BlaZ/BlaP/MecA induction,
the inactivation of the homologous BlaI/MecI repressors is
achieved by the same mechanism. It combines all the observations
and deductions found in the literature for MecA/BlaZ/BlaP
induction in S. aureus, B. licheniformis and B. subtilis. In the case of B.
subtilis, the coactivator-repressor complex is insensitive to cyto-
plasmic proteases [12]. Furthermore, the BlaZ/BlaP/MecA
expression is the consequence of the integration of multiple
signals: BlaR1 acylation, PBP(s) inactivation, and cellular stress
due to the presence of the inducer leading to the triggering of
autolytic enzymes. The integration of all these ON inputs drives
the output of a new AND gate regulation involving a
peptidoglycan fragment [39].
In conclusion, our observations emphasize the muropeptide
catabolic pathway present in B. subtilis [40,41] and the role of
peptidoglycan fragments in the signalling of b-lactam antibiotic
stress response. It adds a new dimension to the emerging multiple
roles of bacterial cell wall fragments in a surprisingly wide range of
important biological phenomena. Indeed, different pathways are
now known to be triggered by peptidoglycan fragments such as
germination of B. subtilis dormant spores [42], induction of the
AmpC b-lactamase in Gram-negative bacteria [43] and human
innate immunity response involving Nod and peptidoglycan
recognition proteins (PGRPs) [44,45]. On the other hand, B.
subtilis cell envelope stress responses include regulons controlled by
s
M elicited by antibiotics, s
W, s
B and several two-component
regulating systems [46]. In all these responses, the molecular
effector signalling the cell envelope stress is missing. Could a
peptidoglycan fragment be the general molecule controlling these
regulons in B. subtilis and more generally in all Eubacteria? If so,
this study on b-lactamase induction opens new ways for
investigation and elucidation of bacterial cell regulation mecha-
nisms.
Materials and Methods
Bacterial strains and plasmids
Bacillus subtilis 168 (ATCC 23857) was used as the host for
pDML995 plasmid, a derivative of the Bacillus/Escherichia coli
shuttle vector pMK4 [47] carrying the wild type B. licheniformis
749/I blaP-blaIR1 divergon, since this last strain is not transform-
able, preventing its easy genetic manipulation. B. subtilis 168 was
transformed as described previously [48].
Luria-Bertani (LB) was used as liquid or solid (1.5% agar
supplemented) medium for growing cells. Cultures were incubated
at 37uC, with continuous shaking (250 rpm, Innova Shaker, New
Brunswick Scientific Co.). Recombinant B. subtilis were selected
with 7 mg/ml chloramphenicol.
The plasmid BlaIWTHis was constructed as described [49].
The plasmid MecIWTHis was constructed as follows: mecI from
Staphylococcus aureus ATCC 43300 was amplified by PCR using
Figure 3. EMSA of BlaI/MecI.OP complex in presence of dipeptide. (A) Effect of c-D-Glu-m-A2pm on BlaI2.OP complex. Two procedures were
tested: either all compounds were added at the same time (lanes 1–2) or BlaI2.OP complex was formed prior to the addition of the dipeptide (lanes 3–
4). For lanes 1, 2, 3, 4 and 6, 1 nmol BlaI and 50 pmol OP were used to form BlaI2.OP complex. For lanes 1 and 3, 10 nmol of c-D-Glu-m-A2pm
(dipeptide 1) were added, whereas 100 nmol were added in lanes 2 and 4. Lane 5: 50 pmol of OP. Total volume: 20 ml. (B) Titration of BlaI2.OP
complex by the c-D-Glu-m-A2pm dipeptide. After BlaI2.OP complex formation (1 nmol BlaI and 50 pmol OP), the dipeptide was added in increasing
amounts: 10, 15, 20, 25, 30, 35, 40, 45 and 50 nmol, respectively (lanes 1–9). Total volume: 20 ml. (C) Titration of MecI2.OP complex by the c-D-Glu-L-
Lys dipeptide. After MecI2.OP complex formation (1 nmol MecI and 50 pmol OP), the dipeptide was added in increasing amounts: 10, 15, 20, 25, 30,
35, 40, 45 and 50 nmol, respectively (lanes 1–9). Total volume: 20 ml. EMSA were carried out on agarose gels. For details see Materials and Methods.
doi:10.1371/journal.ppat.1002571.g003
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PLoS Pathogens | www.plospathogens.org 9 March 2012 | Volume 8 | Issue 3 | e1002571Figure 4. Characterization of the direct interaction between BlaI/MecI repressors and the dipeptide ligands using STD methods and
chemical shift mapping by NMR. (A) Aliphatic region of
1H spectrum of c-D-Glu-m-A2pm (top panel) and the STD experiments performed on the
same peptide after the addition of BlaI repressor at a [Ligand]/[Protein] ratio of 50 (bottom panel). (B) Aliphatic region of the spectrum collected on c-
D-Glu-L-Lys fragments (top panel) and the STD experiments performed on the same peptide after the addition of the MecI repressor at a [Ligand]/
[Protein] ratio of 50 (bottom panel). For (A) and (B), peaks labeled with a star correspond to dipeptide resonances that can be unambiguously
assigned to a saturation transfer from the protein to the ligand, pointing out the direct interaction between the repressor and the peptidoglycan
fragment. The few other peaks present in the STD experiment can be assigned to residual protein signals. They can be observed in STD experiments
recorded on free protein samples. (C and D)
15N and
1H chemical shift variations observed on MecI in presence of different concentrations of c-D-Glu-
L-Lys dipeptide. The left panel (C) shows a region of Sofast-HMQC experiments performed on MecI repressor upon dipeptide addition. Spectrum of
free MecI is plotted in black. Sofast-HMQCs displayed in different colors correspond to experiments collected on the same protein sample upon
successive additions of dipeptide in order to obtain [Dipeptide]/[Protein] ratios of 10, 20, 30, 40 and 50 (plotted in red, green, blue, yellow and
magenta, respectively). The right panel (D) shows the titration curve of the chemical shift perturbations observed on the
15N-
1H correlation spectrum
of MecI for different concentrations of c-D-Glu-L-Lys dipeptide ([Ligand]/[Protein] ratios are displayed).
15N and
1H chemical shift variations were
measured in Hz for peaks, added and finally divided by the number of selected peaks to obtain an average value. The final affinity constant was
862 mM. Error was estimated by Monte-Carlo simulations by assuming that a plateau is reached at a [Ligand]/[Protein] ratio of 50.
doi:10.1371/journal.ppat.1002571.g004
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PLoS Pathogens | www.plospathogens.org 11 March 2012 | Volume 8 | Issue 3 | e1002571primers mecIUP: 59-GAGCATATGGATAATAAAA CGTAT-
GAAATATCATC-39 and mecIDW: 59-CTCGAGTTTATT-
CAATATATTTCTCAATTCTTCTA-39 (NdeI and XhoI recog-
nition sequences respectively are in bold in the primer sequences).
The 410 bp amplicon obtained was purified from agarose gel
(PCR DNA and Gel Band Purification Kit, GE Healthcare) and
cloned into pCR4.TOPO plasmid (Invitrogen), yielding pCRme-
cIHis. The latter plasmid was replicated in E. coli TOP10, purified,
and both strands of the cloned fragment were verified by
sequencing. The pCRmecIHis was digested by NdeI and XhoI
(Promega, Madison) and the fragment cloned into NdeI and XhoI
predigested pET22b (plasmid mecIHispET22b). In-frame cloning
was verified by restriction digestion and sequencing. Six additional
histidine residues at the C-terminal end of MecI were introduced
in this protein by in-frame fusion of 39 end of mecI and the
pET22b.
Restriction endonucleases were purchased from Promega,
Madison. Oligonucleotides were obtained from Eurogentec,
Belgium. LA Taq Polymerase was provided by Takara Bio Inc.
Routine DNA manipulations were performed as described by
Sambrook and Russel [50]. DNA sequencing was performed by
the dideoxy chain termination method using an ALFexpress
sequencer (GE Healthcare Life Sciences).
Overexpression and purification of MecI and BlaI
BlaI-His and MecI-His were, respectively, produced and
purified as described previously [49,51]. When proteins were
overproduced for further RMN analysis, the same purification
strategy was followed, but cells were grown in M9 medium [26]
prepared with
15NH4Cl.
Cellular extract preparation
B. subtilis 168 freshly transformed with plasmid pDML995
(BS995) was grown overnight in a small volume of LB
supplemented with 7 mg/ml of chloramphenicol. The pre-culture
was then diluted 1:50 (v:v) and incubated until an A600 nm of 0.6–
0.8 was reached, when 2.5 mg/ml of the inducer cephalosporin C
(final concentration) were added. Samples were taken at different
times (depending on ulterior experiments) and centrifuged. The b-
lactamase activity was determined in the supernatant by
monitoring the hydrolysis of 100 mM nitrocefin. The cellular
pellet was treated as follows:
(i) Small scale: cells were collected in DNA binding buffer
[10 mM NaHPO4, pH 7.5, 50 mM KCl, 5% glycerol,
50 mg/ml BSA protease and nuclease free (Sigma Chemical
Company)] and sonicated (3 bursts, 30 sec, pulse mode). The
soluble cellular extract was recovered by centrifugation
(2 min, 130006 g in a bench top microcentrifuge) and
poured onto a 500 ml Vivaspin 10 kD protein concentrator
(Sartorius). The filtrate, containing molecules smaller than
the concentrator cut-off, was heated at 100uC for 10 min.
The final protein concentration in this preparation was
determined by the BCA protein assay kit (Pierce). If needed,
an additional fractionation of filtrate was carried out by using
a Vivaspin 5 kD protein concentrator (Sartorius).
(ii) Scaling up: cells from a 2 liter culture, induced for 85–
95 min, were collected in DNA binding buffer and disrupted
by 3 passages through a French Press (SLM instruments,
Urbana, IL). The soluble cellular extract was recovered by
centrifugation at 19000 rpm for 30 min in a Sorvall RC5
centrifuge (SS34 rotor) and filtered through a 20 ml Vivaspin
10 kD protein concentrator following the manufacturer
instructions (Sartorius). The filtrate was heated at 100uC
for 10 min and then centrifuged at 19000 rpm for 40 min.
This treated cellular extract was then freeze-dried and
resuspended in 1 ml of water for further utilization.
Electrophoretic mobility shift assay (EMSA)
Two methods were used:
(i) By using a 0.5 mM OP1 fluorescent double strand oligonu-
cleotide: (59-Cy5-GCATTTAAATCTTACATATGTAA-
TACTTTC-39) and 13.5 mM BlaI or MecI. They were
allowed to form a complex in DNA binding buffer, for
150 min. Then, 250 mg of proteins coming from cellular
extracts or different concentrations of peptides, amino acids
or cell wall derivates were added in a final volume of 10 ml.
The mixture was incubated overnight at 4uC and for an
additional hour at 30uC. The band shift assay was carried out
using an ALF express DNA sequencer [12,14].
(ii) By using the 2.5 mM double strand oligonucleotide and BlaI
or MecI (50 mM). The complex was allowed to form in DNA
binding buffer for 150 min at 30uC and its formation was
checked by agarose gel electrophoresis. Then, different
concentrations of dipeptides (from 10 to 50 fold the
concentration of BlaI or MecI) were added to the complex
and incubated overnight at 4uC and for 60 min at 30uC. Five
ml of glycerol were added to the reaction mixtures before
loading on a 1% (w:v) agarose gel where bound and unbound
oligonucleotides were separated by conventional gel electro-
phoresis. DNA was visualized by ethidium bromide staining.
Source of putative coactivators
The sources and the structures of the compounds tested in this
study as putative coactivators are listed in Table 1.
The dipeptide c-D-Glu-m-A2pm was generated by treatment of
the tripeptide L-Ala-c-D-Glu-m-A2pm with aminopeptidase M
(Roche Applied Science). The reaction mixture (100 ml) containing
50 mM sodium phosphate buffer pH 7.6, 1 mM tripeptide and
Figure 5. New model proposed for b-lactamase induction in B. licheniformis 749/I. (A) Without penicillin outside the cell, the BlaR penicillin
receptor is not activated, BlaI dimer interacts with its nucleic operators (OP1, OP2 and OP3) and BlaP b-lactamase expression is maintained at a low
level. PBP1 involved in the latest step of peptidoglycan biosynthesis is fully active and indirectly involved in cell wall turnover. Indeed, the
incorporation of new glycan chains in the preexisting peptidoglycan network requires its partial hydrolysis. Peptidoglycan fragments generated by
cell wall turnover are reused by B. licheniformis 749/I cells as source of carbon or nitrogen. The cytoplasmic YkfA, B, C and D proteins are probably part
of a catabolic network involved in the use of peptidoglycan fragments generated by cell wall turnover. For more details see the text. (B) In presence
of a concentration of penicillin such that the BlaR receptor and PBP1 are fully and partially acylated, respectively, two signals are generated into the
bacterial cell. Partial PBP1 inactivation would generate a penicillin stress that would increase the cell wall turnover and the accumulation of
peptidoglycan fragments in the cytoplasm. The penicillin-activated BlaR receptor would hydrolyze the L-Ala-c-D-Glu-m-A2pm tripeptide, resulting
from the activity of YkfA, to generate the c-D-Glu-m-A2pm dipeptide. In this scheme, the tripeptide and the dipeptide are the pro-coactivator linked
to blaR2 locus and the coactivator capable to inactivate the BlaI repressor, respectively. The binding of the coactivator to BlaI leads to the inactivation
and subsequent release of the repressor in the cytoplasm where it can be hydrolyzed by cytoplasmic proteases.
doi:10.1371/journal.ppat.1002571.g005
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The complete conversion of the tripeptide in Ala and dipeptide
was confirmed by analysis of an aliquot with the aminoacid
analyzer (Hitachi L8800, Science Tec). The dipeptide was then
purified by HPLC on a Nucleosil 5C18 column (4.66250 mm)
using elution with 0.1% trifluoroacetic acid at a flow rate of
0.6 ml/min. Detection was performed at l=215 nm. Dipeptides
1 and 2 were also obtained by direct synthesis (Nathalie Teller,
PhD Thesis, unpublished data).
The purity of the final products obtained for this study was
verified by mass spectrometry and NMR spectroscopy (1D
1H
experiment).
NMR samples
The
15N BlaI sample concentration was 0.3 mM in a 75 mM
NaH2PO4/Na2HPO4 buffer pH 7.6, containing 300 mM KCl in
1H2O:
2H2O 90:10 (v:v). To study the interaction, 94 mlo fa
sample of c-D-Glu-m-A2pm was prepared at 69.5 mM in the
previous buffer. The pH was adjusted to 7.6 before addition of the
ligand in the
15N BlaI sample. The final protein:ligand ratio
obtained was 1:50.
For the
15N MecI repressor, the sample was prepared at a
concentration of 0.25 mM in 50 mM NaH2PO4/Na2HPO4
buffer, pH 7.6, containing 500 mM NaCl, 1 mM NaN3 in
1H2O:
2H2O 90:10 (v:v). The dipeptide c-D-Glu-L-Lys, involved
in the complex formation, was dissolved at a concentration of
100 mM in a buffer identical to the one used for the
15N MecI
sample.
STD experiments
Saturation Transfer Difference (STD) experiments [52,53] were
acquired at 25uC on a 600 MHz Varian Inova spectrometer
equipped with a penta (
1H/
2H/
13C/
15N/
31P) resonance probe
with shielded z-gradients. In the sequence, saturation of a narrow
band was achieved by a long pulse of 2.5 s at field strength of
48 Hz and was preceded by a supplementary recovery time of 1 s.
The on-resonance irradiation of the protein was applied at a
chemical shift of 0.8 ppm and 0.48 ppm for MecI and BlaI
repressors, respectively. Using samples containing only the ligand
or only the protein, the frequency of the selective saturation can be
adjusted to improve the saturation transfer to the rest of the
protein without affecting the peptide resonances. Off-resonance
irradiation was set to 211.6 ppm, where no protein signals were
present. The difference of the spectra recorded with on-resonance
(Isat) and off-resonance (Iref) saturation provides the STD response:
ISTD~Iref{Isat
The spectra were substracted internally via phase cycling after
every scan to minimize artifacts arising from spectrometer
instabilities. For a target with a very large molecular mass,
transverse relaxation is fast and permits to exclusively detect the
signal corresponding to the free form of the substrate. In the case
of the BlaI and MecI systems, a supplementary transversal
relaxation filter was added to improve the cancellation of the
protein signal. Based on differences of transversal relaxation rates
between small and large molecular mass molecules, a spinlock was
applied using a MLEV-16 [54] phase cycling at a field strength of
4000 Hz. The addition of such a pulse drastically reduces the
protein signals without an important decrease of the signal of the
free ligand. The pulse duration was adjusted to 200 ms in order to
optimize the protein signal cancellation. Water suppression was
finally achieved at the end of the sequence using a WATERGATE
block [55]. Spectral signatures of the two dipeptides were obtained
by recording one-dimensional NMR spectra of the dipeptides in
absence of protein (Figure 4A–B). Peak identification was allowed
thanks to two-dimensional TOCSY spectra collected on the free
ligands in solution (data not shown).
Heteronuclear experiments
1H-
15N heteronuclear correlation experiments were measured
on a 800 MHz Varian Inova spectrometer equipped with a triple
(
1H/
13C/
15N) cryogenic probe with shielded z-gradient. Regular
HSQC spectra were recorded in total experimental times of 10 h
with a spectral resolution of 17 Hz and 10 Hz in the direct and
indirect dimensions, respectively. For sensibility improvement,
SOFAST-HMQC sequence [56] was used with a 120 degree
selective excitation of 2.25 ms duration. Concomitantly, a
polychromatic PC9 shape, centered at 8.5 ppm and covering a
bandwidth of 4 ppm, was required. Selective inversion was
achieved using r-SNOB shape centered at 8 ppm and covering a
bandwidth of 4 ppm. Spectral resolution was set to 43 Hz and
25 Hz in the indirect and direct dimensions, respectively.
Recovery time was set to 0.3 s for a total experimental time of
17 h and 1 h in the case of experiments recorded for titration.
Dissociation constant determination
As described previously, increasing amounts of the peptidogly-
can fragment (c-D-Glu-L-Lys) were successively added to the
protein sample (S. aureus MecI). SOFAST-HMQC experiments,
with an experimental time of 1 h, were recorded on a 600 MHz
spectrometer after each addition of a small volume (10 ml) of a
concentrated solution of dipeptide (100 mM). Thus, dilution was
limited thanks to the availability of large quantities of the
chemically synthesized ligand. Five spectra were collected upon
dipeptide addition. Chemical shift variations measured indicated
that the interaction partners were in fast exchange regarding the
NMR time scale (Figure 4C). Only well-resolved peaks with a
significant signal to noise ratio were considered in the fitting
process. Standard second order polynomial expression was
required to extract the affinity constant value (Figure 4D).
Collected data were analyzed assuming that the detected chemical
shift modification is a weighted average between the two extremes
corresponding to the free (Dd=0) and the bound states
(Dd=Ddmax) [57]. A statistical analysis using Monte-Carlo
simulations was performed to estimate the uncertainty of the
processed data. Fit process and curve visualization were completed
owing to the xmgrace software (http://plasma-gate.weizmann.ac.
il/Grace/).
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